MannKind Reports Positive Phase 1b INFLO-1 Results, Demonstrating Safety and Tolerability of Nintedanib DPI and Clinical Validation of Its DPI Technology in IPF

Generally well-tolerated with no serious adverse events, bronchospasm or diarrhea; no study drug discontinuations 90% of patients had no [60%] or ...
Medscape

Nintedanib Dose Reductions in IPF May Do No Harm

HONOLULU, Hawaii — There's new evidence to support a practice that many pulmonologists have been doing empirically anyway: namely, reducing the dose of the antifibrotic medication nintedanib (Ofev) ...
MedPage Today

Check SSc-ILD Patients on Ofev for Malnutrition, Study Suggests

During nintedanib (Ofev) treatment for interstitial lung disease associated with systemic sclerosis (SSc-ILD), clinicians prescribing the drug should be watchful for an unusual, indirect side effect, ...
The American Journal of Managed Care

Patients With IPF Face QOL Challenges With Antifibrotic Treatment

Antifibrotic treatments for IPF, such as pirfenidone and nintedanib, are associated with significant side effects impacting quality of life. Despite side effects, patients perceive antifibrotics as ...

MannKind Corporation (MNKD) Discusses Phase 1b Results and Clinical Progress of Nintedanib DPI for IPF Transcript

Good afternoon, and welcome to the MannKind Corporation conference call to discuss the Phase 1b results for its nintedanib DPI. As a reminder, this call is being recorded on July 29, 2026, and will be ...
MedPage Today

Gut-Friendlier Dose of Nintedanib Finally Backed by Some Data

HONOLULU -- A reduced-dose regimen of the antifibrotic medication nintedanib (Ofev) held up in real-world clinical practice, an observational study found. Approved for the treatment of idiopathic ...
Pharmabiz

MannKind announces positive results from phase 1b INFLO-1 study of nintedanib DPI to treat idiopathic pulmonary fibrosis IPF

MannKind announces positive results from phase 1b INFLO-1 study of nintedanib DPI to treat idiopathic pulmonary fibrosis IPF: Danbury, Connecticut Thursday, July 30, 2026, 18:00 H ...
ascopubs.org

Effects of nintedanib (BIBF 1120) on QTc interval in previously untreated patients with renal cell cancer (RCC): Results from an open-label, phase II study.

Survival and prognostic factors after complete response to first-line cisplatin-based chemotherapy in patients with advanced testicular seminoma: The Instituto Nacional de Enfermedades Neoplásicas ...
Healio

Patients receiving nintedanib for SSc-ILD at increased risk for malnutrition vs placebo

Please provide your email address to receive an email when new articles are posted on . The rate of malnutrition in the study population was generally low. Rheumatologists should consider patients’ ...